nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

09.09.2019 | Original Article

New insight on the correlation of metabolic status on ¹⁸F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer

verfasst von: Yang Wang, Ning Zhao, Zhanbo Wu, Na Pan, Xuejie Shen, Ting Liu, Feng Wei, Jian You, Wengui Xu, Xiubao Ren

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Metabolic information obtained through ¹⁸F-flurodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) is used to evaluate malignancy by calculating the glucose uptake rate, and these parameters play important roles in determining the prognosis of non-small cell lung cancer (NSCLC). The expression of immune-related markers in tumor tissue reflects the immune status in the tumor microenvironment. However, there is lack of reports on the association between metabolic variables and intra-tumor immune markers. Herein, we investigate the correlation between metabolic status on ¹⁸F-FDG PET/CT and intra-tumor immunomarkers’ expression in NSCLC patients.

Methods

From April 2008 to August 2014, 763 patients were enrolled in the analysis to investigate the role of maximum standardized uptake value (SUVmax) in lung cancer. One hundred twenty-two tumor specimens were analyzed by immunohistochemistry (IHC) to intra-tumor immune cells and programmed death protein ligand 1(PD-L1) expression on tumor cells. The correlation between metabolic variables and the expression of tissue immune markers were analyzed.

Results

SUVmax values have significant variations in different epidermal growth factor receptor (EGFR) statuses (wild type vs mutant type), high/low neutrophil-to-lymphocyte ratio (NLR) groups, and high/low platelets-to-lymphocyte ratio (PLR) groups (p < 0.001, p < 0.001, p = 0.003, respectively). SUVmax was an independent prognostic factor in lung cancer patients (p = 0.013). IHC demonstrated a statistically significant correlation between SUVmax and the expression of CD8 tumor-infiltrating lymphocytes (p = 0.015), CD163 tumor-associated macrophages (TAMs) (p = 0.003), and Foxp3-regulatory T cells (Tregs) (p = 0.004), as well as PD-1 and PD-L1 (p = 0.003 and p = 0.012, respectively). With respect to patient outcomes, disease stage, BMI, SUVmax, metabolic tumor volume (MTV), TLG (tumor lesion glycolysis), CD163-TAMs, CD11c-dendritic cells (DCs), PD-L1, and Tregs showed a statistically significant correlation with progression-free survival (PFS) (p < 0.001, 0.023, < 0.001, 0.007, 0.005, 0.004, 0.008, 0.048, and 0.014, respectively), and disease stage, SUVmax, MTV, TLG, CD163-TAMs, CD11c-DCs, and PD-L1 showed a statistically significant correlation with overall survival (OS) (p < 0.001, < 0.001, 0.014, 0.012, < 0.001, 0.001, and < 0.001, respectively).

Conclusion

This study revealed an association between metabolic variable and immune cell expression in the tumor microenvironment and suggests that SUVmax on ¹⁸F-FDG PET/CT could be a potential predictor for selecting candidates for immunotherapy.

Nur mit Berechtigung zugänglich

Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med. 2012;13:287–97.PubMed

Ashamalla H, Rafla S, Parikh K, Mokhtar B, Goswami G, Kambam S, et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys. 2005;63:1016–23. https://doi.org/10.1016/j.ijrobp.2005.04.021.CrossRefPubMed

Mac MM, Hicks RJ. The role of positron emission tomography/computed tomography in radiation therapy planning for patients with lung cancer. Semin Nucl Med. 2012;42:308–19. https://doi.org/10.1053/j.semnuclmed.2012.04.003.CrossRef

Opoka L, Szolkowska M, Podgajny Z, Kunikowska J, Baranska I, Blasinska-Przerwa K, et al. Assessment of recurrence of non-small cell lung cancer after therapy using CT and Integrated PET/CT. Pneumonol Alergol Pol. 2013;81:214–20.PubMed

Palsson-McDermott EM, O’Neill LA. The Warburg effect then and now: from cancer to inflammatory diseases. Bioessays. 2013;35:965–73. https://doi.org/10.1002/bies.201300084.CrossRefPubMed

Appelberg R, Moreira D, Barreira-Silva P, Borges M, Silva L, Dinis-Oliveira RJ, et al. The Warburg effect in mycobacterial granulomas is dependent on the recruitment and activation of macrophages by interferon-gamma. Immunology. 2015;145:498–507. https://doi.org/10.1111/imm.12464.CrossRefPubMedPubMedCentral

Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014–22. https://doi.org/10.1038/ni.2703.CrossRefPubMedPubMedCentral

Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309–22. https://doi.org/10.1016/j.ccr.2012.02.022.CrossRefPubMed

Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. https://doi.org/10.1038/nrc3245.CrossRefPubMed

10.

Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329–60. https://doi.org/10.1146/annurev.immunol.22.012703.104803.CrossRefPubMed

11.

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39. https://doi.org/10.1056/NEJMoa1507643.CrossRefPubMedPubMedCentral

12.

Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–50. https://doi.org/10.1016/S0140-6736(15)01281-7.CrossRefPubMed

13.

Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837–46. https://doi.org/10.1016/S0140-6736(16)00587-0.CrossRefPubMed

14.

Chang CH, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162:1229–41. https://doi.org/10.1016/j.cell.2015.08.016.CrossRefPubMedPubMedCentral

15.

Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity. 2013;38:633–43. https://doi.org/10.1016/j.immuni.2013.04.005.CrossRefPubMedPubMedCentral

16.

Na F, Wang J, Li C, Deng L, Xue J, Lu Y. Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis. J Thorac Oncol. 2014;9:834–42. https://doi.org/10.1097/JTO.0000000000000185.CrossRefPubMedPubMedCentral

17.

Nair VS, Krupitskaya Y, Gould MK. Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review. J Thorac Oncol. 2009;4:1473–9. https://doi.org/10.1097/JTO.0b013e3181bccbc6.CrossRefPubMed

18.

Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte JJ, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol. 2010;5:612–9. https://doi.org/10.1097/JTO.0b013e3181d0a4f5.CrossRefPubMed

19.

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44. https://doi.org/10.1038/nature07205.CrossRef

20.

Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:u124. https://doi.org/10.1093/jnci/dju124.CrossRef

21.

Liu H, Wu Y, Wang Z, Yao Y, Chen F, Zhang H, et al. Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer. J Thorac Dis. 2013;5:783–9. https://doi.org/10.3978/j.issn.2072-1439.2013.12.34.CrossRefPubMedPubMedCentral

22.

Kaya V, Yildirim M, Demirpence O, Yildiz M, Yalcin AY. Prognostic significance of basic laboratory methods in non- small-cell-lung cancer. Asian Pac J Cancer Prev. 2013;14:5473–6.CrossRef

23.

Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30:1073–81. https://doi.org/10.1093/carcin/bgp127.CrossRefPubMed

24.

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45. https://doi.org/10.1016/S0140-6736(00)04046-0.CrossRefPubMed

25.

Elkord E, Alcantar-Orozco EM, Dovedi SJ, Tran DQ, Hawkins RE, Gilham DE. T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther. 2010;10:1573–86. https://doi.org/10.1517/14712598.2010.529126.CrossRefPubMed

26.

Na II, Byun BH, Kim KM, Cheon GJ, Choe DH, Koh JS, et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer. 2010;67:76–80. https://doi.org/10.1016/j.lungcan.2009.03.010.CrossRefPubMed

27.

Mak RH, Digumarthy SR, Muzikansky A, Engelman JA, Shepard JA, Choi NC, et al. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist. 2011;16:319–26. https://doi.org/10.1634/theoncologist.2010-0300.CrossRefPubMedPubMedCentral

28.

Higashi K, Ueda Y, Sakurai A, Mingwang X, Xu L, Murakami M, et al. Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancer. Eur J Nucl Med. 2000;27(12):1778–85. https://doi.org/10.1007/s002590000367.CrossRefPubMed

29.

Wei T, Zhang J, Qin Y, Wu Y, Zhu L, Lu L, et al. Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients. Am J Cancer Res. 2015;5:2190–201.PubMedPubMedCentral

30.

Jayaraman P, Jacques MK, Zhu C, Steblenko KM, Stowell BL, Madi A, et al. TIM3 mediates t cell exhaustion during Mycobacterium tuberculosis infection. PLoS Pathog. 2016;12:e1005490. https://doi.org/10.1371/journal.ppat.1005490.CrossRefPubMedPubMedCentral

31.

Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol. 2008;180:5916–26.CrossRef

32.

Rabe H, Nordstrom I, Andersson K, Lundell AC, Rudin A. Staphylococcus aureus convert neonatal conventional CD4(+) T cells into FOXP3(+) CD25(+) CD127(low) T cells via the PD-1/PD-L1 axis. Immunology. 2014;141:467–81. https://doi.org/10.1111/imm.12209.CrossRefPubMedPubMedCentral

33.

Hasegawa T, Suzuki H, Yamaura T, Muto S, Okabe N, Osugi J, et al. Prognostic value of peripheral and local forkhead box P3+ regulatory T cells in patients with non-small-cell lung cancer. Mol Clin Oncol. 2014;2:685–94. https://doi.org/10.3892/mco.2014.299.CrossRefPubMedPubMedCentral

34.

Bille A, Okiror L, Skanjeti A, Errico L, Arena V, Penna D, et al. The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients: analysis of 413 cases. Clin Lung Cancer. 2013;14:149–56. https://doi.org/10.1016/j.cllc.2012.04.007.CrossRefPubMed

35.

Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016;43:1954–61. https://doi.org/10.1007/s00259-016-3425-2.CrossRefPubMed

36.

Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol. 2005;5:844–52. https://doi.org/10.1038/nri1710.CrossRefPubMed

37.

Jones RG, Thompson CB. Revving the engine: signal transduction fuels T cell activation. Immunity. 2007;27:173–8. https://doi.org/10.1016/j.immuni.2007.07.008.CrossRefPubMed

38.

van Bruggen R, Koker MY, Jansen M, van Houdt M, Roos D, Kuijpers TW, et al. Human NLRP3 inflammasome activation is Nox1–4 independent. Blood. 2010;115:5398–400. https://doi.org/10.1182/blood-2009-10-250803.CrossRefPubMed

39.

Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467–77. https://doi.org/10.1038/nri2326.CrossRefPubMed

40.

Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9:562–7. https://doi.org/10.1038/nm863.CrossRefPubMed

41.

Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–34.CrossRef

42.

Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–93. https://doi.org/10.1016/j.cell.2012.03.017.CrossRefPubMedPubMedCentral

43.

Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer. 2014;2:3. https://doi.org/10.1186/2051-1426-2-3.CrossRefPubMedPubMedCentral

Titel: New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer
verfasst von: Yang Wang
Ning Zhao
Zhanbo Wu
Na Pan
Xuejie Shen
Ting Liu
Feng Wei
Jian You
Wengui Xu
Xiubao Ren
Publikationsdatum: 09.09.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 5/2020
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04500-7

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

New insight on the correlation of metabolic status on ¹⁸F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer

Abstract

Background

Methods

Results

Conclusion

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Prognostic significance of semi-quantitative FDG-PET parameters in stage I non-small cell lung cancer treated with carbon-ion radiotherapy

The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer

Lymphoscintigraphy and sentinel lymph node biopsy in vulvar carcinoma: update from a European expert panel

Augmented planar bone scintigraphy obtained from a whole-body SPECT recording of less than 20 min with a high-sensitivity 360° CZT camera

18F-FDG PET/CT in diagnostic and prognostic evaluation of patients with cardiac masses: a retrospective study

Diagnostic performance of 18F-FDG PET/CT in patients with spinal infection: a systematic review and a bivariate meta-analysis